Safety and efficacy of the switch to generic mycophenolate mofetil and tacrolimus in heart-transplant patients.

Carl Söderlund, Göran Rådegran

Forskningsoutput: TidskriftsbidragArtikel i vetenskaplig tidskriftPeer review

Sammanfattning

Generic immunosuppressants may offer economic advantages, but their use is still controversial. At our centre, 55 heart-transplant patients were switched from CellCept(®) to Myfenax Teva(®) (MT) (n=51, 18% female, 8.1±6.6 years post-transplantation) and/or Prograf(®) to Tacrolimus Sandoz(®) (TS) (n=17, 41% female, 6.6±5.8 years post-transplantation).
Originalspråkengelska
Sidor (från-till)619-628
TidskriftClinical Transplantation
Volym29
Nummer7
DOI
StatusPublished - 2015

Ämnesklassifikation (UKÄ)

  • Kardiologi

Fingeravtryck

Utforska forskningsämnen för ”Safety and efficacy of the switch to generic mycophenolate mofetil and tacrolimus in heart-transplant patients.”. Tillsammans bildar de ett unikt fingeravtryck.

Citera det här